Mr. Bill Meury is the former Chief Executive Officer of Anthos Therapeutic, a Blackstone Life Sciences portfolio company, which was acquired by Novartis in April 2025. Mr. Meury joined Anthos after leading Karuna Therapeutics, a biopharmaceutical company focused on neuroscience, until its merger with Bristol Meyers Squibb in March 2024. Prior to Karuna, he served as a Partner at Hildred Capital Management, a private equity firm focusing on healthcare products and services. Prior to Hildred Capital Management, he was Executive Vice President and Chief Commercial Officer at Allergan, where he had responsibility for over 50 products with $16 billion in revenue and over $3 billion in operating investment. In this role, he led multiple global divisions totaling 7,500 employees, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Mr. Meury has extensive experience across a broad range of therapeutics areas, including neuroscience, cardiovascular, gastroenterology, dermatology, and ophthalmology and has been involved with over 20 FDA approvals and new product launches. He also served as Allergan’s President, Branded Pharma, and Executive Vice President, Commercial, North American Brands and as Executive Vice President Commercial Operations, at Forest Laboratories prior to its acquisition by Allergan. He currently serves on the board of directors of Syndax Pharmaceuticals and The Jed Foundation. Mr. Meury received his bachelor’s degree in economics from the University of Maryland.